Ironwood Pharmaceuticals (NASDAQ:IRWD) Upgraded at Wall Street Zen

by · The Markets Daily

Wall Street Zen upgraded shares of Ironwood Pharmaceuticals (NASDAQ:IRWD – Free Report) from a buy rating to a strong-buy rating in a research note issued to investors on Saturday,Wall Street Zen reports.

Several other brokerages have also commented on IRWD. Weiss Ratings raised shares of Ironwood Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Jefferies Financial Group raised shares of Ironwood Pharmaceuticals to a “hold” rating in a research note on Friday, September 25th. Finally, Zacks Research lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.23.

View Our Latest Stock Report on Ironwood Pharmaceuticals

Ironwood Pharmaceuticals Price Performance

IRWD opened at $4.68 on Friday. The stock has a market capitalization of $773.32 million, a price-to-earnings ratio of 5.20 and a beta of 0.25. The business has a 50-day moving average of $3.92 and a two-hundred day moving average of $3.96. Ironwood Pharmaceuticals has a 12 month low of $2.31 and a 12 month high of $5.78.

Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.36 EPS for the quarter, beating analysts’ consensus estimates of $0.32 by $0.04. The company had revenue of $133.04 million during the quarter, compared to the consensus estimate of $119.99 million. Ironwood Pharmaceuticals had a net margin of 33.36% and a negative return on equity of 58.38%. Equities research analysts anticipate that Ironwood Pharmaceuticals will post 1.10 earnings per share for the current year.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

A number of large investors have recently modified their holdings of IRWD. Principal Financial Group Inc. acquired a new position in shares of Ironwood Pharmaceuticals in the 1st quarter valued at about $40,000. Y Intercept Hong Kong Ltd acquired a new stake in Ironwood Pharmaceuticals during the 1st quarter worth approximately $47,000. Bull Harbor Capital LLC acquired a new stake in Ironwood Pharmaceuticals during the 1st quarter worth approximately $48,000. Ascent Group LLC acquired a new stake in Ironwood Pharmaceuticals during the 3rd quarter worth approximately $58,000. Finally, DGS Capital Management LLC raised its holdings in Ironwood Pharmaceuticals by 42.8% in the first quarter. DGS Capital Management LLC now owns 14,883 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 4,458 shares during the period.

About Ironwood Pharmaceuticals

(Get Free Report)

Ironwood Pharmaceuticals, Inc is a gastrointestinal-focused biopharmaceutical company headquartered in Boston, Massachusetts. The company discovers, develops, and commercializes medicines intended to treat disorders affecting the gastrointestinal tract, with an emphasis on conditions involving gut motility and visceral sensitivity.

Ironwood’s principal commercial product is Linzess (linaclotide), marketed in the United States in collaboration with AbbVie. Linzess is approved for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation.

Further Reading